Table A2.

GLI1 Quartiles by Patient and Disease Characteristics

Characteristic	GLI1 Quartiles								All
	Q1		Q2		Q3		Q4
	No.	%	No.	%	No.	%	No.	%	No.	%
Treatment
Standard	20	23.8	17	20.7	17	19.3	24	28.2	78	23.0
Hypofractionation	25	29.8	22	26.8	32	36.4	21	24.7	100	29.5
Split-course accelerated fractionation	23	27.4	22	26.8	20	22.7	23	27.1	88	26.0
Accelerated fractionation with concomitant boost	16	19.0	21	25.6	19	21.6	17	20.0	73	21.5
Sex
Male	64	76.2	62	75.6	72	81.8	65	76.5	263	77.6
Female	20	23.8	20	24.4	16	18.2	20	23.5	76	22.4
KPS
60	7	8.3	2	2.4	3	3.4	4	4.7	16	4.7
70	8	9.5	7	8.5	17	19.3	16	18.8	48	14.2
80	16	19.0	15	18.3	24	27.3	20	23.5	75	22.1
90	44	52.4	41	50.0	32	36.4	36	42.4	153	45.1
100	9	10.7	17	20.7	12	13.6	9	10.6	47	13.9
Age, years
≤ 55	20	23.8	32	39.0	25	28.4	32	37.6	109	32.2
56-65	28	33.3	27	32.9	35	39.8	29	34.1	119	35.1
≥ 66	36	42.9	23	28.0	28	31.8	24	28.2	111	32.7
Primary site
Oral cavity	8	9.5	6	7.3	12	13.6	7	8.2	33	9.7
Oropharynx	47	56.0	47	57.3	47	53.4	50	58.8	191	56.3
Hypopharynx	10	11.9	12	14.6	10	11.4	11	12.9	43	12.7
Larynx	19	22.6	17	20.7	19	21.6	17	20.0	72	21.2
T stage
T1	—	—	5	6.1	3	3.4	2	2.4	10	2.9
T2	31	36.9	16	19.5	15	17.0	21	24.7	83	24.5
T3	33	39.3	40	48.8	40	45.5	35	41.2	148	43.7
T4	20	23.8	21	25.6	30	34.1	27	31.8	98	28.9
N stage
N0	19	22.6	23	28.0	23	26.1	14	16.5	79	23.3
N1	18	21.4	20	24.4	16	18.2	24	28.2	78	23.0
N2a	6	7.1	6	7.3	6	6.8	8	9.4	26	7.7
N2b	17	20.2	13	15.9	17	19.3	16	18.8	63	18.6
N2c	15	17.9	15	18.3	17	19.3	13	15.3	60	17.7
N3	9	10.7	5	6.1	9	10.2	10	11.8	33	9.7

Abbreviations: GLI1, glioma-associated oncogene family zinc finger 1; Q, quartile; KPS, Karnofsky performance score.